Drug Approval | August 06, 2025
AbbVie submits for FDA approval of Venclexta and Acalabrutinib combination for untreated CLL patients
The submission is supported by positive results from the Phase 3 AMPLIFY trial
The submission is supported by positive results from the Phase 3 AMPLIFY trial
The submission is supported by results from the Phase 3b APEX study
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
It is intended for contrast enhancement in MRI scans
Most recently he served as Chief Operating Officer at Bharat Serums and Vaccines
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
Subscribe To Our Newsletter & Stay Updated
